ASH 2022 | Phase I/II study of MS-553, a selective PKC-ß Inhibitor, in patients with CLL and SLL
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, highlights the initial findings of a Phase I/II dose-expansion study of MS-553 (NCT03492125), a novel and selective protein kinase C beta (PKC-β) inhibitor, in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Overall, the preliminary findings indicate that MS-553 has initial anti-tumor activity in this heavily pre-treated population. Common adverse effects include fatigue and gastrointestinal (GI) toxicities, but MS-553 was generally well tolerated. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So, MS-553 is an inhibitor of protein kinase C beta or PKC-ß, and this has actually been demonstrated in preclinical studies to be an important target in CLL and actually some other B-cell malignancies as well. So this again was a Phase I dose escalation study, reached a recommended Phase II dose and continuing on an expansion phase at this time. It’s looking very effective in terms of having activity, especially at lymph node shrinkage in patients who have received multiple prior therapies, even some who had received both covalent and non-covalent BTK inhibitors, as well as patients who had received venetoclax before...
So, MS-553 is an inhibitor of protein kinase C beta or PKC-ß, and this has actually been demonstrated in preclinical studies to be an important target in CLL and actually some other B-cell malignancies as well. So this again was a Phase I dose escalation study, reached a recommended Phase II dose and continuing on an expansion phase at this time. It’s looking very effective in terms of having activity, especially at lymph node shrinkage in patients who have received multiple prior therapies, even some who had received both covalent and non-covalent BTK inhibitors, as well as patients who had received venetoclax before.
Side effect profile, again, generally well tolerated. We do see some fatigue with this drug as well as some GI toxicities, but those seem to be things that happen more early on if treated with a higher dose and tend to be more tolerable over time.
So looking really exciting. I’m excited to see what happens with longer term follow-up of these patients as well as more patients being accrued.
Read more...
Disclosures
Karyopharm Therapeutics: Research Funding; Schrodinger: Research Funding; Newave: Consultancy; Genentech: Consultancy; Pharmacyclics: Consultancy; ArQule: Consultancy; MorphoSys: Consultancy, Research Funding; Loxo@Lilly: Research Funding; AbbVie: Consultancy, Research Funding; Janssen: Consultancy; BeiGene: Consultancy; AstraZeneca: Consultancy.
